Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) will host its quarterly earnings conference call for the second quarter of 2021 on July 22, 2021, at 8:00 a.m. ET. The call will last approximately one hour and will be available for live streaming on the company's website. A replay will be accessible shortly after the call until August 5, 2021. Pre-call dial-in is available for U.S. and international participants. Earnings materials will be posted on Danaher’s investor section starting at 6:00 a.m. ET on the day of the call.
SCIEX launches the ZenoTOF 7600 system, an advanced mass LC-MS/MS instrument, enhancing the identification and quantification of biomolecules. This system promises up to 20x greater sensitivity and can quantify 40% more proteins than previous models while analyzing samples 5x faster. The integrated Zeno trap and electron activated dissociation (EAD) fragmentation enable researchers to explore post-translational modifications and biomarker discovery effectively, pushing boundaries in precision diagnostics and biopharmaceutical development.
SCIEX has enhanced its software portfolio, launching the OneOmics suite, which facilitates big data processing in multi-omics research via secure cloud computing. This suite allows researchers to analyze large proteomics and metabolomics datasets significantly faster. Additionally, the Molecule Profiler app aids in identifying and quantifying biopharmaceutical metabolites and impurities. The SCIEX OS software ecosystem, now supporting the ZenoTOF 7600 system, ensures data integrity and streamlines workflows for scientists across multiple labs.
Danaher Corporation (NYSE: DHR) announced its agreement to acquire Aldevron for approximately $9.6 billion, enhancing Danaher's presence in genomic medicine. Aldevron, founded in 1998, specializes in high-quality plasmid DNA, mRNA, and proteins, and will operate as a standalone entity within Danaher’s Life Sciences segment. The acquisition aims to support the development of cell, gene therapies, and vaccines. The transaction is subject to customary regulatory approvals.
On June 7, 2021, Danaher Corporation (NYSE: DHR) announced that its Executive Vice President and CFO, Matt McGrew, will present at the Goldman Sachs Global Healthcare Conference on June 8, 2021, at 2:10 p.m. ET. The presentation will be available via a live webcast on www.danaher.com. Danaher is recognized as a global leader in science and technology, focusing on healthcare and environmental sectors, and operates with around 69,000 employees, all committed to enhancing quality of life.
Danaher Corporation (NYSE: DHR) announced that its Executive Vice President and CFO, Matt McGrew, will present at the Jefferies Healthcare Conference on June 2, 2021, at 1:00 p.m. ET. The presentation will be available via a live webcast on Danaher's official website. Danaher is a leader in science and technology, focusing on solving complex challenges and improving global quality of life. With over 69,000 associates, Danaher operates more than 20 companies across health care, environmental, and applied end-markets.
Danaher Corporation (NYSE: DHR) announced the appointment of A. Shane Sanders to its Board of Directors and Audit Committee, increasing the board size to thirteen members. Sanders, currently Senior Vice President of Business Transformation at Verizon Communications Inc. (NYSE: VZ), has extensive experience in corporate finance, having served in leadership roles since joining Verizon in 1997. His qualifications include a B.S. in Accounting and an M.B.A. His appointment is expected to enhance Danaher's leadership and support its goal of building long-term shareholder value.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.21 per share on its common stock, payable on July 30, 2021, to shareholders on record as of June 25, 2021. Additionally, the company announced dividends of $11.875 per share for its 4.75% Series A Mandatory Convertible Preferred Stock and $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock, both payable on July 15, 2021, with record dates of June 30, 2021.
Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, presenting at the Bank of America Healthcare Conference on May 11, 2021, at 2:00 p.m. ET. The presentation will be webcast live on Danaher's official website. Danaher is recognized as a global leader in science and technology, focusing on solving complex challenges across health care, environmental, and applied end-markets. With over 69,000 employees, Danaher operates more than 20 companies unified by the Danaher Business System, dedicated to enhancing quality of life worldwide.
Danaher Corporation (NYSE: DHR) has established a Scientific Advisory Board to bolster its innovation and investment strategies. The Board comprises renowned scientists, including two Nobel laureates, who will aid in assessing M&A opportunities and guiding early-stage investments. Their role involves collaborating with Danaher’s leadership to enhance scientific innovations essential for global health. CEO Rainer Blair emphasized the Board's key role in aligning Danaher’s scientific agenda with evolving healthcare needs. This strategic move aims to strengthen Danaher's competitive edge and accelerate advancements in health technologies.